Update on quinolone-containing rescue therapies for Helicobacter pylori infection

Table 3 Sitafloxacin-containing therapies

Ref.	Country	X-line	Publication year	Drug combination (per day)	Duration (d)	Eradication rate (%)
						ITT	PP
Matsuzaki et al[8]	Japan	3rd	2012	STFX 200 mg + AMX 2000 mg + RPZ 40 mg	7	78.2	83.6
Murakami et al[58]	Japan	3rd	2013	STFX 200 mg + AMX 1500 mg + LPZ 60 mg	7	70.0	72.1
Furuta et al[86]	Japan	3rd	2014	STFX 200 mg + AMX 2000 mg + RPZ 20-40 mg	7	84.1	86.4
Furuta et al[86]	Japan	3rd	2014	STFX 200 mg + AMX 2000 mg + RPZ 20-40 mg	14	88.9	90.9
Furuta et al[86]	Japan	3rd	2014	STFX 200 mg + MTZ 500 mg + RPZ 20-40 mg	7	90.9	90.9
Furuta et al[86]	Japan	3rd	2014	STFX 200 mg + MTZ 500 mg + RPZ 20-40 mg	14	87.2	91.1
Mori et al[9]	Japan	3rd	2015	STFX 200 mg + AMX 2000 mg + EPZ 40 mg	10	81.0	82.0
Mori et al[9]	Japan	3rd	2015	STFX 200 mg + MTZ 500 mg + EPZ 40 mg	10	72.4	76.4
Sue et al[87]	Japan	3rd	2019	STFX 200 mg + AMX 1500 mg + PPI	7	53.3	57.1
Sue et al[87]	Japan	3rd	2019	STFX 200 mg + AMX 1500 mg + VPZ 40 mg	7	75.8	83.3

ITT: Intention-to-treat; PP: Per Protocol; STFX: Sitafloxacin; AMX: Amoxicillin; RPZ: Rabeprazole; LPZ: Lansoprazole; EPZ: Esomeprazole; MTZ: Metronidazole; PPI: Proton pump inhibitors; VPZ: Vonoprazan.